FISH VACCINE MARKET ANALYSIS

Fish Vaccine Market Size and Trends

Global fish vaccine market is estimated to be valued at USD 375.1 million in 2024 and is expected to reach USD 691.2 million by 2031, exhibiting a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031.

Discover market dynamics shaping the industry request sample copy

Rising cases of viral infections are encouraging fish farmers and government organizations to adopt preventive measures. Furthermore, increasing adoption of advanced vaccine administration techniques and growing aquaculture industry can boost demand for high quality and effective fish vaccines. However, high vaccination cost and lack of infrastructure and awareness in developing nations can hamper the market growth.  Increasing R&D investment by major players for development of novel vaccines and growing consumer preference for safe seafood are expected to create lucrative opportunities for the fish vaccine market in the near future.

Global Aquaculture Boom

Rising demand for fish and other seafood products across the world has led to tremendous growth in commercial aquaculture industry in the past few years. Due to growing world population and increased seafood consumption, farmed fish production needs to keep pace to satisfy this demand. Many countries and private firms have extensively invested in developing commercial fish farming operations to boost fish yields. Salmon, carp, tilapia, shrimp and other popular varieties are now extensively cultivated in fish farms and ponds on a large industrial scale. However, intensive aquaculture increases risk of diseases that can spread rapidly and devastate entire stocks, if left uncontrolled. Vaccines have emerged as a critical tool for fish farmers to immunize their stocks and minimize losses from endemic diseases. As the aquaculture sector expands to new geographies and scales new heights to meet  seafood demand, the dependence on reliable fish health management solutions including vaccines will increase substantially.

Market Concentration and Competitive Landscape

Get actionable strategies to beat competition: Get instant access to report

Changing Disease Dynamics

Climate change alters environmental conditions in unpredictable ways which can influence the epidemiology of infectious diseases. Rising water temperatures and other shifts in weather patterns may enable certain fish pathogens to spread more easily. Moreover, as fish farming intensifies through higher stocking densities, greater transboundary trade in live fish, and more stress on cultured stocks, these changes can render populations more vulnerable to outbreaks. Several emergent diseases have already appeared that threaten commercial stocks. For instance, piscine orthoreovirus was linked to largescale salmon losses in Chile and Norway. Koi herpesvirus also caused severe carotenoid disease in common and koi carp globally. As new pathogens emerge and existing ones mutate, fish breeders will require innovative vaccination strategies and solutions to protect their investments and bolster disease resilience in farmed fish populations. The evolving pathogen risk landscape emphasizes the necessity of reliable immunization as a fundamental tool for sustainable aquaculture worldwide.

Key Takeaways from Analyst:

Global fish vaccine market can witness growth in the near future. As the consumption of fish continues to rise worldwide due to growing population and health awareness, there will be huge demand for fish vaccine to counter various diseases prevalent in the aquaculture industry. Rising demand for seafood and emergence of zoonotic fish diseases can drive the fish vaccine market growth globally. However, stringent regulations surrounding vaccine development and high R&D costs associated with the vaccine development can hamper the market growth during the forecast period.

Regions like Asia Pacific and Latin America hold immense potential for market expansion owing to rising seafood trade and growing acceptance of preventive healthcare among fish farmers. Within Asia Pacific, markets in China, India, and other Southeast Asian nations are expected to generate sizable revenues for fish vaccine manufacturers due to the region's dominant position in global fish production. North America and Europe will continue dominating the developmental activities for advanced vaccine products. Viral and bacterial vaccines are likely to witness higher uptake against economically important diseases such as Vibriosis and Streptococcosis.

Rising focus on sustainable aquaculture practices and formulation of effective regional immunization programs can present lucrative opportunities for stakeholders. Leading players should strengthen their distribution networks across fast-developing regions and invest in R&D.

Market Challenges: Stringent regulatory approvals.

Strict regulations surrounding the development and use of antibiotics and antimicrobials in aquaculture can hamper the market growth. The high cost of R&D for new vaccines can also pose challenges for market growth. Maintaining cold chain logistic and distribution also poses difficulties in many markets. Sustainable and environment-friendly practices call for alternative measures to antibiotics.

Market Opportunities: Booming aquaculture industry

Rising fish consumption globally and booming aquaculture industry, the demand for vaccines is surging to prevent disease outbreak and maintain good health of farmed fish. Advances in vaccine development technology to produce efficacious yet cost-effective vaccines will promote their greater usage. Many new markets remain untapped which can be further developed.

Discover high revenue pocket segments and roadmap to it: Get instant access to report

Insights, By Vaccine Type:  Efficacy and Prevention from Severe Diseases

In terms of vaccine type, inactivated vaccine segment is estimated to contribute the highest market share of 45.10% in 2024, owing to its high efficacy and ability to prevent severe diseases. Inactivated vaccines are rendered non-infectious through chemical or physical means while still retaining their immunogenic properties. These stimulate strong protective immune responses in fish without causing the disease. This provides fish robust and long-lasting protection against the target pathogens. Inactivated vaccines have been found to be more effective than live attenuated vaccines in preventing mortality and outbreaks from various bacterial and viral infections. Their inability to replicate also makes them safe for fish of all ages and health conditions. The high safety and efficacy profile of inactivated vaccines has increased their demand from fish farmers looking to minimize losses from diseases.

Insights By Indication: High Prevalence and Mortality Rates

In terms of indication, furunculosis segment is estimated to contribute the highest market share of 25.50% due to the severe impact and widespread prevalence of Aeromonas salmonicida. Furunculosis, commonly known as fish tuberculosis, is caused by A. salmonicida bacteria. It affects various cold-water fish species including salmon and trout. The disease has high mortality rates, sometimes killing entire population stocks. Left unchecked, it can devastate fish farms and wild fisheries. With no effective treatment available, vaccination is critical for controlling outbreaks and reducing economic losses. The development of improved furunculosis vaccines has been critical in establishing sustainable aquaculture industries globally. Growing aquaculture production can boost demand for furunculosis vaccines.

Insights, By Route of Administration- Ease of Administration and Mass Immunization

In terms of route of administration, injection segment is estimated to contribute the highest market share of 60% in 2024 , owing to the advantages it offers over other methods. While immersion and spray may allow mass treatment, injection ensures precise delivery of the right vaccine dose for optimal immune response in individual fish. It also leads to faster protection against diseases. The hypodermic injection technique is well-established in the aquaculture industry, allowing rapid vaccination of large numbers of fish. Injection vaccines are simple to administer and does not require specialized equipment. These achieve higher immune response levels as compared to immersion/spray when vaccinating high-value fish. With its targeted delivery and superior immunization outcomes, injection will remain a preferred administration route.

Regional Insights

To learn more about this report, request sample copy

North America has been leading the global fish vaccine market, accounting for over 36.2%% of total transplants worldwide last year. The region's dominance is attributed to its advanced transplant centers, supportive reimbursement policies, and increasing awareness. The U.S. alone holds a market twice the size of any other country. Key medical device companies in North America invest heavily in research and development, ensuring continuous innovation in immunosuppressants, organ preservation solutions, and diagnostic tools for transplants. The region also imports organs due to a demand-supply imbalance.

However, Asia Pacific has emerged as the fastest-growing market due to rising chronic kidney disease incidences, growing incomes, and government initiatives to boost organ donation. China, in particular, has witnessed increase in transplants due to efforts to enhance local production, change donation rules, and increase affordability. This has attracted global medical technology firms to invest in partnerships and local manufacturing in China, reflecting the region's promising growth prospects.

Market Report Scope

Fish Vaccine Industry News

• On January 5, 2024, according to the World Organization for Animal Health, a project in the Philippines is underway to create a vaccine against the Tilapia Lake Virus (TiLV), a newly identified viral pathogen
• In November 2022, Indian Immunologicals (IIL), a veterinary and human biologicals company, partnered with the Central Institute of Freshwater Aquaculture (CIFA),a research institute, to develop a vaccine against hemorrhagic septicemia in freshwater fish. The partnership aims to combat common bacterial diseases in these fish, including Columnaris Disease and Edwardsiellosis. CIFA, under ICAR, will provide the technology for the vaccines.

*Definition: Global fish vaccine market consists of vaccines that prevent bacterial and viral infections in fish. The vaccines help protect farmed fish and promote their growth and survival. Major fish-producing nations are driving the market as these aim to meet the rising global demand for fish and seafood in a sustainable manner. The market has witnessed steady growth over the past few years due to increasing fish farming activities and greater awareness among fish farmers about the benefits of vaccination. Advancements in vaccine technology have also contributed to the market expansion.

Market Segmentation

•  Vaccine Type Insights (Revenue, USD Mn, 2019 - 2031)
  • Killed Vaccine
  • Inactivated Vaccine
  • Attenuated Vaccine
  • Toxoid Vaccine
  • Subunit Vaccine
  • Conjugate Vaccine
  • Recombinant Vector Vaccines
•  Indication Insights (Revenue, USD Mn, 2019 - 2031)
  • Furunculosis
  • Vibriosis
  • Yersiniosis
  • Enteric septicaemia
  • Others
•  Route Of Administration Insights (Revenue, USD Mn, 2019 - 2031)
  • Injection
  • Immersion
  • Spray
  • Oral
• Regional Insights (Revenue, USD Mn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Merck Animal Health (MSD Animal Health)
  • Zoetis
  • Elanco
  • Virbac
  • HIPRA
  • Veterquímica S.A.
  • Tecnovax
  • Phibro Animal Health Corporation
  • Ridgeway Biologicals Ltd.
  • Nisseiken Co., Ltd.
  • Aquatic Animal Health Ltd
  • Ictyogroup
  • Benchmark Holdings plc
  • Vaxxinova
  • Alpha Biotech Ltd.
  • Vallee S.A.
  • Ringpu Biology
  • Nippon Zenyaku Kogyo Co., Ltd.
  • Chengdu Tech-bank Biological Products
  • Weiyuan Gene Tech